Darwin Discovery Limited

Sosei R&d Ltd.

Medeva Europe Limited

Celltech Pharma Europe Limited

Closed Loop Medicine Ltd.

Andrew John McGlashan Richards

Julian Clive Gilbert

John Nicholas Staniforth

Robin Mark Bannister

David A V Morton

Hazel Judith Bardsley

Nicholas Robert Pope

Laurence E Mather

Robert William Gristwood

David Cox

Paul Goldsmith

Hakim Adam Yadi

Felicity Kate Sartain

David O'Regan

The present disclosure relates to methods and systems suitable for use in identifying and providing personalised medicine to a patient. In some aspects, systems and method generate a co-therapy regimen for a patient suffering from a disease or condition. An identification of a co-therapy suitable to treat the disease or condition is received. A desired patient endpoint and a patient position are received, wherein the patient position is defined relative to the desired patient endpoint. A dataset relating to the patient is stored. The dataset comprises one or more patient data based on patient-related measurements. The dataset, the patient position and the desired patient endpoint are processed to generate a regimen for the co-therapy. The regimen is stored in a database.

Methods and systems for providing personalised medicine to a patient

A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.

Treatment of respiratory diseases

A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with Pmetabolism, wherein the methylphenidate is d-threo-methylphenidate.

Composition comprising methylphenidate and another drug

Treatment of respiratory disease

A unit dosage and pharmaceutical delivery system for anaesthetizing a human patient prior to major surgery, which comprise between 200 mg and 300 mg of levobupivacaine.

Levobupivacaine and its use

A process of treating a subject that is undergoing methylphenidate therapy and concomitant therapy with another drug undergoes or interferes with P metabolism, wherein the methylphenidate is d-threo-methylphenidate.

Levobupivacaine ((S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide) is useful as an anesthetic, particularly in a patient who is disposed to adverse systemic side-effects, e.g., one who is CNS-compromised or predisposed to CNS side-effects. A unit dose of levobupivacaine comprising at least 75 mg to less than 200 mg of levobupivacaine is described herein.

Levobupivacaine as an analgesic agent

A pharmaceutical dosage form comprises, in a portion thereof, substantially single enantiomer (R)-verapamil and, in another, separate, portion thereof, substantially single enantiomer (S)-verapamil, wherein, in use, the different enantiomers are released at different rates from the dosage form.

Dosage forms and uses

A pharmaceutical dosage form comprises, in one portion thereof, a substantially single (&plus;)-enantiomer of a chiral drug other than verapamil and, in another, separate portion thereof, a substantially single (&minus;)-enantiomer of the drug wherein, in use, the different enantiomers are released at different rates from the dosage form. The dosage form is useful for administration of chiral drugs where both enantiomers have a valid pharmacological input, and where a clinical benefit may be realised by controlling the release rates of those enantiomers. Examples of such drugs include, in particular, tramadol and warfarin.

Dosage forms

A method of anesthetizing a human patient prior to major surgery, which comprises the administration to the patient of at least 200 mg levobupivacaine.

Growing community of inventors

Cambridge, United Kingdom

Andrew John McGlashan Richards